Generic Drugs Stock Performance Review -- Momenta Pharma, Medicines Co., Diplomat Pharmacy, and Zoetis

Wednesday, October 4, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 4, 2017 /PRNewswire/ --

If you want a Stock Review on MNTA, MDCO, DPLO, or ZTS then come over to and sign up for your free customized report. Ahead of today's trading session, shifts focus on Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), The Medicines Co. (NASDAQ: MDCO), Diplomat Pharmacy
Inc. (NYSE: DPLO), and Zoetis Inc. (NYSE: ZTS). According to a Research and Markets report, the US is the biggest Generic Drugs market in the world. In fact, nearly 80% of the prescriptions written in the US are for generic drugs. These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Momenta Pharmaceuticals 

Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock finished Tuesday's session 2.51% lower at $17.50. A total volume of 717,116 shares was traded, which was above their three months average volume of 557,180 shares. Over the last month and the previous three months, the Company's shares have advanced 4.48% and 2.64%, respectively. Additionally, the stock has gained 16.28% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.83% and 10.50%, respectively. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have a Relative Strength Index (RSI) of 51.61.

On September 28th, 2017, research firm Goldman initiated a 'Neutral' rating on the Company's stock, with a target price of $18 per share.

On October 02nd, 2017, Momenta Pharma announced the promotion of Dr. Ganesh Kaundinya to Chief Operating Officer (COO). Dr. Kaundinya, who assumed his new position effective September 25th, 2017, will also continue to serve as Chief Scientific Officer and report directly to Craig Wheeler, the Company's President and CEO. Your complete research report on MNTA can be retrieved for free at:

Medicines Co. 

Shares in Parsippany, New Jersey-based The Medicines Co. rose 0.31%, ending yesterday's session at $38.30 with a total trading volume of 1.11 million shares. The stock has gained 1.24% in the past month and 12.85% on an YTD basis. The Company's shares are trading 5.00% above their 50-day moving average. Moreover, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 61.96.  

On September 28th, 2017, Medicines Co. announced that data from its portfolio of antimicrobial products will be featured in presentations at IDWeek 2017 to be held from October 04th, 2017 to October 08th, 2017, in San Diego. The Company's infectious disease research and product development is focused on the most serious multi-drug resistant infections, including carbapenem-resistant Enterobacteriaceae. A free report on MDCO is just a click away at:

Diplomat Pharmacy 

On Tuesday, Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock climbed 1.00%, to close the day at $21.25. A total volume of 503,574 shares was traded. The Company's shares have surged 27.17% in the last one month, 43.48% in the previous three months, and 68.65% on an YTD basis. The stock is trading 21.35% and 33.90% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 71.03.  

On October 02nd, 2017, Diplomat Pharmacy (DPLO) has acquired 8th Day Software and Consulting, LLC. Based in Tennessee, the latter will operate under DPLO subsidiary, Envoy Health Management LLC. Dave Loschinskey, founder of 8th Day, becomes DPLO's Chief Information Officer. Sign up for your complimentary research report on DPLO at:


Shares in Parsippany, New Jersey headquartered Zoetis Inc. ended the day 0.25% lower at $63.59. A total volume of 1.66 million shares was traded. The stock has gained 1.15% in the last one month, 1.66% in the previous three months, and 18.79% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 1.50% and 9.03%, respectively. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 48.94.  

On September 26th, 2017, Zoetis announced that it has been named one of the top ten companies on Working Mother magazine's "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave, and childcare. Register for free on and download the latest research report on ZTS at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store